The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Financial support is being provided as a grant from the Government of India
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Subscribe To Our Newsletter & Stay Updated
